Deep Vein Thrombosis (DVT) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) – Pipeline Review, H2 2016’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT)

The report reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Deep Vein Thrombosis (DVT) therapeutics and enlists all their major and minor projects

The report assesses Deep Vein Thrombosis (DVT) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc.

Dong-A Socio Holdings Co. Ltd.

F. Hoffmann-La Roche Ltd.

Generex Biotechnology Corporation

Laboratorios Farmaceuticos Rovi, S.A.

Pharmathen Pharmaceuticals S.A.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Deep Vein Thrombosis (DVT) Overview 7

Therapeutics Development 8

Pipeline Products for Deep Vein Thrombosis (DVT) - Overview 8

Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis 9

Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies 10

Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes 11

Deep Vein Thrombosis (DVT) - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Deep Vein Thrombosis (DVT) - Products under Development by Companies 15

Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes 16

Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development 17

3SBio Inc. 17

Dong-A Socio Holdings Co. Ltd. 18

F. Hoffmann-La Roche Ltd. 19

Generex Biotechnology Corporation 20

Laboratorios Farmaceuticos Rovi, S.A. 21

Pharmathen Pharmaceuticals S.A. 22

Deep Vein Thrombosis (DVT) - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

Antisense RNAi Oligonucleotide for Deep Vein Thrombosis - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

ARC-15105 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

CM-20201 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

enoxaparin sodium biosimilar - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

enoxaparin sodium biosimilar - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

enoxaparin sodium biosimilar - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

fondaparinux sodium - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

STP-023725 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

TRX-1 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Deep Vein Thrombosis (DVT) - Dormant Projects 42

Deep Vein Thrombosis (DVT) - Discontinued Products 43

Deep Vein Thrombosis (DVT) - Product Development Milestones 44

Featured News & Press Releases 44

Aug 22, 2016: New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer’s Xarelto Accepted for Presentation at ESC Congress 2016 44

May 18, 2016: Janssen to Present Data on Rivaroxaban at the 2016 American Society of Clinical Oncology Annual Meeting 47

Apr 25, 2016: Patent Term for Rivaroxaban Extended in US 48

Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials 48

Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy 49

Dec 07, 2015: Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis 50

Nov 30, 2015: New Data from Bayer’s Portfolio in Thrombosis to be Presented at ASH 2015 51

Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015 51

Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting 53

May 04, 2015: Bayer’s Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis 54

Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents 55

Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits 55

Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 57

Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 58

Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

List of Tables

Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2016 8

Number of Products under Development for Deep Vein Thrombosis (DVT) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Deep Vein Thrombosis (DVT) – Pipeline by 3SBio Inc., H2 2016 17

Deep Vein Thrombosis (DVT) – Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 18

Deep Vein Thrombosis (DVT) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 19

Deep Vein Thrombosis (DVT) – Pipeline by Generex Biotechnology Corporation, H2 2016 20

Deep Vein Thrombosis (DVT) – Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2016 21

Deep Vein Thrombosis (DVT) – Pipeline by Pharmathen Pharmaceuticals S.A., H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Deep Vein Thrombosis (DVT) – Dormant Projects, H2 2016 42

Deep Vein Thrombosis (DVT) – Discontinued Products, H2 2016 43

List of Figures

List of Figures

Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2016 8

Number of Products under Development for Deep Vein Thrombosis (DVT) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Targets, H2 2016 24

Number of Products by Mechanism of Actions, H2 2016 26

Number of Products by Stage and Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports